The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Role of epidermal growth factor receptor in breast cancer
Open accessAbstract
Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy—e.g., as a chemosensitizer or to prevent metastases—to treat these aggressive diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“EGFR overexpression is found in at least 50 % of cases of TNBC, which is a higher expression rate than the rates seen in other breast cancer subtypes [44].”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Isaacson, P. G., Dogan, A., Price, S. K., & Spencer, J. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198912000-00004 · Cited by 1,915
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Richard, J., Sainsbury, C., Needham, G., Farndon, J., Malcolm, A., & Harris, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90593-9 · Cited by 892
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 695
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 680
Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?
Thompson, E. W., & Newgreen, D. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0616 · Cited by 667
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Self-citationActivation of the Erk Pathway Is Required for TGF-β1-Induced EMT In Vitro
Xie, L., Law, B. K., Chytil, A. M., Brown, K. A., Aakre, M. E., & Moses, H. L. (2004) · Neoplasia · doi:10.1593/neo.04241 · Cited by 523
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Dawood, S., Merajver, S. D., Viens, P., Vermeulen, P. B., Swain, S. M., Buchholz, T. A., Dirix, L. Y., Levine, P. H., Lucci, A., Krishnamurthy, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq345 · Cited by 488
Self-citationTargeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Di Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S. F., Koehler, M., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 418
Epithelial-mesenchymal transition
Radisky, D. C. (2005) · Journal of Cell Science · doi:10.1242/jcs.02552 · Cited by 417
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355
Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
Reis‐Filho, J., Pinheiro, C., Lambros, M., Milanezi, F., Carvalho, S., Savage, K., Simpson, P., Jones, C., Swift, S., Mackay, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2004 · Cited by 266
EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma
Yatabe, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000157935.28066.35 · Cited by 237
Doehn, U., Hauge, C., Frank, S. R., Jensen, C. J., Duda, K., Nielsen, J. V., Cohen, M. S., Johansen, J. V., Winther, B. R., Lund, L. R., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.002 · Cited by 227
Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent Oligodendrogliomas
Fallon, K. B., Palmer, C. A., Roth, K. A., Nabors, L. B., Wang, W., Carpenter, M., Banerjee, R., Forsyth, P., Rich, K., & Perry, A. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.4.314 · Cited by 207
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.409 · Cited by 203
Burstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M., & Blackwell, K. L. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm601 · Cited by 203
Smith, I. E., Walsh, G., Skene, A., Llombart, A., Mayordomo, J. I., Detre, S., Salter, J., Clark, E., Magill, P., & Dowsett, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6578 · Cited by 201
Johnston, S., Trudeau, M., Kaufman, B., Boussen, H., Blackwell, K., LoRusso, P., Lombardi, D. P., Ben Ahmed, S., Citrin, D. L., DeSilvio, M. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9949 · Cited by 195
Polychronis, A., Sinnett, H. D., Hadjiminas, D., Singhal, H., Mansi, J. L., Shivapatham, D., Shousha, S., Jiang, J., Peston, D., Barrett, N., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70176-5 · Cited by 194
Buck, E., Eyzaguirre, A., Barr, S., Thompson, S., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 191
Viale, G., Rotmensz, N., Maisonneuve, P., Bottiglieri, L., Montagna, E., Luini, A., Veronesi, P., Intra, M., Torrisi, R., Cardillo, A., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0206-z · Cited by 190
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
Eccles, S. A. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113396se · Cited by 176
Burness, M. L., Grushko, T. A., & Olopade, O. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24fc1 · Cited by 176
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Dickler, M. N., Cobleigh, M., Miller, K. D., Klein, P. M., & Winer, E. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0055-9 · Cited by 167
von Minckwitz, G., Jonat, W., Fasching, P., du Bois, A., Kleeberg, U., Lück, H.-J., Kettner, E., Hilfrich, J., Eiermann, W., Torode, J., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1720-2 · Cited by 167
Jin, Q., & Esteva, F. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9107-3 · Cited by 156
Epithelial–Mesenchymal Transition in Development and Cancer
Micalizzi, D. S., & Ford, H. L. (2009) · Future Oncology · doi:10.2217/fon.09.94 · Cited by 154
Erlichman, C., Hidalgo, M. M., Boni, J. P., Martins, P., Quinn, S., Zacharchuk, C., Amorusi, P., Adjei, A. A., & Rowinsky, E. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8960 · Cited by 153
Cabıoğlu, N., Gong, Y. Y., Islam, R., Broglio, K. R., Sneige, N., Şahin, A. A., Gonzalez-Angulo, A. M., Morandi, P., BUCANA, C. D., Hortobágyi, G. N., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm060 · Cited by 151
Zhang, D., LaFortune, T. A., Krishnamurthy, S., Esteva, F. J., Cristofanilli, M., Liu, P., Lucci, A., Singh, B., Hung, M., Hortobágyi, G. N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0951 · Cited by 144
Self-citationDickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J. A., Yeh, B. M., Lake, D. E., Dang, C. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0141 · Cited by 127
Zell, J. A., Tsang, W. Y., Taylor, T. H., Mehta, R. S., & Anton‐Culver, H. (2009) · Breast Cancer Research · doi:10.1186/bcr2225 · Cited by 105
A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer
Modi, S., D’Andrea, G. M., Norton, L., Yao, T. J., Caravelli, J. F., Rosen, P., Hudis, C. A., & Seidman, A. D. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.040 · Cited by 104
EGFR/Met association regulates EGFR TKI resistance in breast cancer
Mueller, K. L., Yang, Z.-Q., Haddad, R., Ethier, S. P., & Boerner, J. L. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-8 · Cited by 99
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
Nemunaitis, J. J., Eiseman, I. A., Cunningham, C. C., Senzer, N. N., Williams, A., Lenehan, P. F., Olson, S. C., Bycott, P. W., Schlicht, M., Zentgraff, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1950 · Cited by 88
Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 87
Calvo, E., Tolcher, A. W., Hammond, L. A., Patnaik, A., Bono, J. S. D., Eiseman, I. A., Olson, S. C., Lenehan, P. F., McCreery, H., LoRusso, P. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1187 · Cited by 81
Weber, F., Fukino, K., Sawada, T., Williams, N., Sweet, K. M., Brena, R. M., Plass, C., Caldés, T., Mutter, G. L., Villalona-Calero, M. A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602557 · Cited by 75
Twelves, C. J., Trigo, J. M., Jones, R. J., Rosa, F. D., Rakhit, A. K., Fettner, S. H., Wright, T., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.011 · Cited by 51
Baselga, J. M., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J.-C., Graas, M. P., Kennedy, J. F., Gil, E. C., Zubel, A., Groos, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-pd01-01 · Cited by 49
Garland, L. L., Hidalgo, M. M., Mendelson, D. S., Ryan, D. P., Arun, B. K., Lovalvo, J. L., Eiseman, I. A., Olson, S. C., Lenehan, P. F., & Eder, J. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2507 · Cited by 30
Deconstructing ERK Signaling in Tumorigenesis
Santamaría, P. G., & Nebreda, Á. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.03.012 · Cited by 24
Mauriac, L., Cameron, D., Dirix, L. Y., Blot, E., Piccart, M. J., Marreaud, S. I., Tjan‐Heijnen, V. C. G., Cufer, T., Bogaerts, J., & Başaran, G. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-6133 · Cited by 8
Cited by
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Metadata
- Authors
- Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-10-17
- Volume
- 136
- Issue
- 2
- Pages
- 331-345
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W1988055795
- Cited by
- 806
- References
- 74
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.